Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25167208 | 1.00 | EPHX1 (0.47) | EPHX1MLKLLMNAKDM4EADRB2 | |
| SCHEMBL963917 | 0.98 | EPHX1 (0.46) | EPHX1MLKLLMNAKDM4EADRB2 | |
| SCHEMBL966044 | 0.85 | CA12 (0.39) | EPHX1MLKLLMNAKDM4EADRB2 | |
| SCHEMBL28065142 | 0.85 | CA12 (0.39) | EPHX1MLKLLMNAKDM4EADRB2 | |
| SCHEMBL27741919 | 0.85 | LMNA (0.55) | EPHX1LMNAKDM4EADRB2ADRB1 | |
| SCHEMBL964905 | 0.85 | LMNA (0.55) | EPHX1LMNAKDM4EADRB2ADRB1 | |
| SCHEMBL12129521 | 0.85 | PTGS2 (0.49) | MLKLLMNAKDM4EADRB2ADRB1 | |
| SCHEMBL28065141 | 0.85 | PTGS2 (0.49) | MLKLLMNAKDM4EADRB2ADRB1 | |
| SCHEMBL16322044 | 0.83 | LMNA (0.41) | LMNAKDM4EADRB2ADRB1ADRB3 | |
| SCHEMBL966466 | 0.83 | LMNA (0.41) | LMNAKDM4EADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141355-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | DOMPE' FARMACEUTICI SPA (IT) | 2023-05-11 | — | — | US | claimed |
| EP-4125848-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici SpA (IT) | 2023-02-08 | — | — | EP | claimed |
| CN-115397404-A | CXCL8 inhibitors for the treatment of COVID-19 | 东佩制药股份公司 | 2022-11-25 | — | — | CN | claimed |
| EP-4008325-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-06-08 | — | — | EP | claimed |
| EP-2024329-B1 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2013-07-31 | — | — | EP | claimed |
| US-7868046-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2011-01-11 | — | — | US | claimed |
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2010-06-17 | — | — | US | claimed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | claimed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | claimed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | claimed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | claimed |
| US-12636268-B2 | CXCL8 inhibitors for use in the treatment of COVID-19 | DOMPE' FARMACEUTICI SPA (IT) | 2026-05-26 | — | — | US | disclosed |
| US-20250161248-A1 | Treating Chronic Myelomonocytic Leukemia with CXCL8 Receptor Inhibitors | INSTITUT GUSTAVE ROUSSY (FR) | 2025-05-22 | — | — | US | disclosed |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230151081-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2023-05-18 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | CCR2, CXCR2, CXCR4 | EPHX1 1189/4885MLKL 4234/4885LMNA 3868/4885 |
| US-20230141355-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | CXCL8, CCR8, CXCL10 | EPHX1 706/4885MLKL 327/4885LMNA 4717/4885 |
| US-20230151081-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | EPHX1 1783/4885MLKL 1853/4885LMNA 4124/4885 |
| US-12636268-B2 | CXCL8 inhibitors for use in the treatment of COVID-19 | CXCL8, CCR8, CCL11 | EPHX1 1883/4885MLKL 742/4885LMNA 4772/4885 |
| US-20250161248-A1 | Treating Chronic Myelomonocytic Leukemia with CXCL8 Receptor Inhibitors | CXCL8, CCR8, CSF3R | EPHX1 1538/4885MLKL 68/4885LMNA 4692/4885 |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | EPHX1 1783/4885MLKL 1853/4885LMNA 4124/4885 |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | CCR2, CXCR2, CXCR3 | EPHX1 908/4885MLKL 3818/4885LMNA 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.